by HBOT News | Sep 11, 2019 | Clinical Trials, HBOT Research, Type 2-diabetes
Diabetes mellitus type 2 (T2D) is characterized by insulin resistance of liver and skeletal
muscle, which is at least partly due to impaired muscle mitochondrial function. Long-term HBO
therapy, as applied for treating the diabetic foot syndrome, has been shown to improve blood
glucose concentrations. To study the underlying mechanisms, we want to examin the short-term
effect of HBO treatment on insulin sensitivity and mitochondrial oxidative capacity and
production of reactive oxygen species (ROS) in a randomized, double blinded,
placebo-controlled cross-over trial.
by HBOT News | Aug 17, 2018 | Diabetes, Kidney Disease, Renal Trauma
Diabetic kidney disease (DKD) is the leading cause of end-stage renal failure in the western world. Current treatment of diabetic kidney disease relies on nutritional management and drug therapies to achieve metabolic control. Here, we discuss the potential application of hyperbaric oxygen therapy (HBOT) for the treatment of diabetic kidney disease (DKD), a treatment which requires patients to breathe in 100% oxygen at elevated ambient pressures. HBOT has traditionally been used to diabetic foot ulcers (DFU) refractory to conventional medical treatments. Successful clinic responses seen in the DFU provide the underlying therapeutic rationale for testing HBOT in the setting of DKD. Both the DFU and DKD have microvascular endothelial disease as a common underlying pathologic feature.
by HBOT News | Jul 9, 2018 | Diabetic Foot Ulcers
Several treatment modalities and protocols for ischaemic foot ulcers are available. However, little consensus exists on optimal treatment. The aim of this study was to compare Standard Wound Care (SWC) alone SWC with adjunct hyperbaric oxygen therapy (HBOT) in the treatment of ischaemic Diabetic Foot Ulcers (DFUs). Twenty-six patients with Type 2 Diabetes Mellitus (T2DM) presenting with a newly diagnosed ischaemic foot ulcer were included. These were divided into group A (SWC with adjunct HBOT) and group B (SWC only). Participants were followed every week for 4 weeks and their ulcers were measured for their surface area and depth to assess any change in wound size. Both treatment arms succeeded in reducing ulcer area and depth (p<0.001).
by HBOT News | May 11, 2018 | Diabetes
This study aimed at examining the early effects of hyperbaric oxygen therapy (HBOT) on inducible nitric oxide synthase (iNOS) activity/expression in lymphocytes of type 1 diabetes mellitus (T1DM) patients. A group of 19 patients (mean age: 63 ± 2.1) with T1DM and with the peripheral arterial disease were included in this study. Patients were exposed to 10 sessions of HBOT in the duration of 1 h to 100% oxygen inhalation at 2.4 ATA. Blood samples were collected for the plasma C-reactive protein (CRP), plasma free fatty acid (FFA), serum nitrite/nitrate, and serum arginase activity measurements. Expression of iNOS and phosphorylation of p65 subunit of nuclear factor-B (NFB-p65), extracellular-regulated kinases 1/2 (ERK1/2), and protein kinase B (Akt) were examined in lymphocyte lysates by Western blot.
by HBOT News | Apr 9, 2018 | Cancer News, Diabetes News
KPLC, Lake Charles, LA – LA reporting on the use of Hyperbaric Oxygen Therapy or HBOT as a supplement to tradtional treatment methods to treat secondary injuries and increase quality of live for Diabetes and Cancer patients. Read the full article:...
